Studies on the mode of action of mitomycin C(7) aminoethylene disulfides (BMS-181174 and KW-2149): Reactivity of 7-N-(mercaptoethyl)mitomycin C [3]

Journal of Medicinal Chemistry

Volumn 42, Issue 5, 1999, Pages 788-790

  Wang, Shuang ^a   Kohn, Harold ^a  

^a University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 N [2 (4 NITROPHENYLDITHIO)ETHYL]MITOMYCIN C; 7 N [2 [[2 (GAMMA GLUTAMYLAMINO)ETHYL]DITHIO]ETHYL]MITOMYCIN C; DITHIOTHREITOL; MITOMYCIN C; MITOMYCIN DERIVATIVE; PORFIROMYCIN; THIOL; UNCLASSIFIED DRUG;

CHEMICAL MODIFICATION; CHEMICAL REACTION; CROSS LINKING; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LETTER; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MITOMYCIN; MITOMYCINS; SULFHYDRYL COMPOUNDS;

EID: 0033545643     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9806796     Document Type: Letter

References (43)

1. Carter, S. K.; Crooke, S. T. Mitomycin C. Current Status and New Developments; Academic Press: New York, 1979.
2. (a) Remers, W. A.; Dorr, R. T. In Alkaloids; Chemical and Biological Perspective; Pelletter, S. W., Ed.; Wiley and Sons: New York, 1988; Vol. 6, pp 1-74.
3. (b) Remers, W. A. The Chemistry of Antitumor Antibiotics; Wiley and Sons: New York, 1979; Vol. 1, pp 221-276.
4. Bradner, W. T.; Remers, W. A.; Vyas, D. M. Structure-Activity Comparison of Mitomycin C and Mitomycin A Analogues (Review). Anticancer Res. 1989, 9, 1095-1100.
5. Vyas, D. M.; Chiang, Y.; Benigni, D.; Rose, W. C.; Bradner, W. T.; Doyle, T. W. In Recent Advances in Chemotherapy. Anticancer Section 1; Ishigami, J., Ed.; University of Tokyo Press: Tokyo, 1985; pp 485-486.
6. Kono, M.; Saitoh, Y.; Kasai, M.; Sato, A.; Shirahata, K.; Morimoto, M.; Ashizawa. T. Synthesis and Antitumor Activity of a Novel Water Soluble Mitomycin Analogue; 7-N-[2-[[2-(γ-L-Glutamylamino)ethyl]dithio]ethyl]mitomycin C. Chem. Pharm. Bull. 1989, 37, 1128-1130.
7. (a) Xu, B. H.; Singh, S. V. Effect of Buthionine Sulfoximine and Ethacrynic Acid on Cytotoxic Activity of Mitomycin C Analogues BMY 25282 and BMY 25067. Cancer Res. 1992, 52, 6666-6670.
8. (b) Yen, W.-C.; Au, J. L.-S. Pharmacodynamic Evaluation of Mitomycin C Analogue BMS-181174 for Potential use in Intravesical Bladder Cancer Therapy. Pharm. Res. 1997, 14, 241-245.
9. Dirix, L.; Catimel, G.; Koier, I.; Provè, A.; Schrijvers, D.; Joossens, E.; De Bruijn, E.; Ardiet, C.; Evene, E.; Dumortier, A.; Clavel, M.; Van Oosterom, A. Phase 1 and Pharmacokinetic Study of a Novel Mitomycin C Analogue KW-2149. Anti-Cancer Drugs 1995, 6, 53-63.
10. He, Q.-Y.; Maruenda, H.; Tomasz, M. Novel Bioreductive Activation Mechanism of Mitomycin C Derivatives Bearing a Disulfide Substituent in Their Quinone. J. Am. Chem. Soc. 1994, 116, 9349-9350.
11. Kohn, H.; Wang, S. Studies on the Mechanism of Activation of C(7) Ethylenediamine Substituted Mitomycins. Relevance to the Proposed Mode of Action of BMY-25067 and KW-2149. Tetrahedron Lett. 1996, 37, 2337-2340.
12. For additional mechanistic studies of 3, see: (a) Lee, J.-H.; Naito, M.; Tsuruo, T. Nonenzymatic Reductive Activation of 7-N-{{2-{[2-γ-L-Glutamyl-amino)ethyl]dithio}ethyl}}mitomycin C by Thiol Molecules: a Novel Mitomycin C Derivative Effective on Mitomycin C-resistant Tumor Cells. Cancer Res. 1994, 54, 2398-2403.
13. (b) Masters, J. R. W.; Know, R. J.; Hartley, J. A.; Kelland, L. R.; Hendriks, H. R.; Connors, T. KW-2149 (7-[2-[γ-L-Glutamyl-aminoethyl]dithioethyl]mitomycin C) a New Mitomycin C Analogue Activated by Serum. Biochem. Pharamacol. 1997, 53, 279-285.
14. (c) McAdam, S. R.; Knox, R. J.; Hartley, J. A.; Masters, J. R. W. KW-2149 (7-N-[2-[γ-L-Glutamyl-amino]ethyldithioethyl]-mitomycin C): DNA Interactions and Drug Uptake Following Serum Activation. Biochem. Pharmacol. 1998, 55, 1777-1783.
15. (a) Iyer, V. N.; Szybalski, W. Mitomycins and Porfiromycin: Chemical Mechanism of Activation and Cross-linking of DNA. Science 1964, 145, 55-58.
16. (b) Moore, H. W.; Czerniak, R. Naturally Occurring Quinones as Potential Bioreductive Alkylating Agents. Med. Res. Rev. 1981, 1, 249-280.
17. (c) Schiltz, P.; Kohn, H. Studies on the Reactivity of Reductively Activated Mitomycin C. J. Am. Chem. Soc. 1993, 115, 10510-10518.
18. (d) Kumar, G. S.; Lipman, R.; Cummings, J.; Tomasz, M. Mitomycin C-DNA Adducts Generated by DT-Diaphorase. Revised Mechanism of the Enzymatic Reductive Activation of Mitomycin C. Biochemistry 1997, 36, 14128-14136.
19. (a) Vyas, D. M.; Chiang, Y.; Doyle, T. W. Amino Bisulfide Thiol Exchange Products. U.S. Patent 4,866,180, Sept 12, 1989; Chem. Abstr. 1998, 108, 150167x.
20. (a) Vyas, D. M.; Chiang, Y.; Doyle, T. W. Amino Bisulfide Thiol Exchange Products. U.S. Patent 4,866,180, Sept 12, 1989; Chem. Abstr. 1998, 108, 150167x.
21. (b) Vyas, D. M.; Chiang, Y.; Doyle, T. W. Amino Bisulfides. U.S. Patent 4,803,212, Feb 7, 1989; Chem. Abstr. 1986, 102, 131829z.
22. (b) Vyas, D. M.; Chiang, Y.; Doyle, T. W. Amino Bisulfides. U.S. Patent 4,803,212, Feb 7, 1989; Chem. Abstr. 1986, 102, 131829z.
23. 20a,b) and new (5, 6, 13) compounds. Compounds 7 and 8 were too unstable to isolate. Treatment of either 5 or 6 with GSH provided the corresponding GSH-mitomycin mixed disulfide 7-N-[2-(glutathionedithio)-ethyl]mitomycin C. Additional details can be found in Wang, S. Ph.D. Thesis, University of Houston, Houston, TX, 1998.
24. Cleland, W. W. Dithiothreitol, a New Protective Reagent for SH Groups. Biochemistry 1964, 3, 480-482.
25. Singh, R.; Whitesides, G. M. A Reagent for Reduction of Disulfide Bonds in Proteins that Reduces Disulfide Bonds Faster Than Does Dithiothreitol. J. Org. Chem. 1991, 56, 2332-2337.
26. Kasai, M.; Sato, Y.; Kono, M.; Akira, S.; Hiroshi, S.; Kunikatsu, S.; Makoto, M.; Tadashi, A. Pharmacologically Active Mitomycin Derivatives. Eur. Pat. Appl. EP0197,799, Oct 15, 1986; Chem. Abstr. 1987, 106, 49881j.
27. Kasai, M.; Sato, Y.; Kono, M.; Akira, S.; Hiroshi, S.; Kunikatsu, S.; Makoto, M.; Tadashi, A. Pharmacologically Active Mitomycin Derivatives. Eur. Pat. Appl. EP0197,799, Oct 15, 1986; Chem. Abstr. 1987, 106, 49881j.
28. (a) Patai, S. The Chemistry of the Thiol Group; Wiley: New York, 1974; p 677.
29. (b) Maskill, H. The Physical Basis of Organic Chemistry; Oxford University Press: Oxford, 1985; p 159.
30. 18 μBondapak (stainless steel) column (3.9 x 300 mm) using the following linear gradient 90% A (aqueous 0.025 M triethylammonium acetate, pH 6.5), 10% B (acetonitrile) isocratic for 5 min, then from 90% A, 10% B to 45% A, 55% B in 30 min. The flow rate was 1 mL/min, and the eluent was monitored from 200 to 400 nm.
31. The identities of the major remaining peaks were determined after PTLC isolation, spectroscopic elucidation, and then subsequent confirmation of the product peak in the reaction mixture by co-injection (cospot) of the authentic sample with the reaction solution in the HPLC (TLC).
32. A similar difference in the HPLC retention times was observed for mitomycin C (16.7 min) and porfiromycin (18.1 min).
33. The HPLC data does not exclude multimeric adducts of 4 (12).
34. (a) Kono, M.; Saitoh, Y.; Kasai, M.; Shirahata, K.; Morimoto, M.; Ashizawa, T. Synthesis and Structure-Activity Relationships of New Dimeric Mitomycin Derivatives; 7-N,7'-N'-Bis(ω-thioalkyl)dimitomycins. J. Antibiot. 1983, 46, 1428-1438.
35. (b) Senter, P. D.; Langley, D. R.; Manger, W. E.; Vyas, D. Reassignment of the Structure for the Antitumor Agent RR-150. J. Antibiot. 1988, 41, 199-201.
36. (a) Kobayashi, S.; Ushiki, J.; Takai, K.; Okumura, S.; Kono, M.; Kasai, M.; Gomi, K.; Morimoto, M.; Ueno, H.; Hirata, T. Disposition and Metabolism of KW-2149, a Novel Anticancer Agent. Cancer Chemother. Pharmacol. 1993, 32, 143-150.
37. (b) Ashizawa, T.; Okamoto, A.; Okabe, M.; Kobayashi, S.; Arai, H.; Saito, H.; Kasai, M.; Gomi, K. Characteristics of the Antitumor Activity of M-16 and M-18, Major Metabolites of a New Mitomycin C Derivative KW-2149, in Mice. Anti-Cancer Drugs 1995, 6, 763-770.
38. (a) Hornemann, U.; Keller, P. J.; Kozlowski, J. F. Formation of 1-Ethylxanthyl-2,7-diaminomitosene and 1,10-Diethylxanthyl-2,7-diaminodecarbamoylmitosene in Aqueous Solution upon Reduction-Reoxidation of Mitomycin C in the Presence of Potassium Ethylxanthate. J. Am. Chem. Soc. 1979, 101, 7121-7124.
39. (b) Hornemann, U.; Iguchi, K.; Keller, P. J.; Vu, H. M.; Kozlowski, J. F.; Kohn, H. Reactions of Mitomycin C with Potassium Ethyl Xanthate in Neutral Aqueous Solution. J. Org. Chem. 1983, 48, 5026-5033.
40. (c) Danishefsky, S. J.; Egbertson, M. On the Characterization of Intermediates in the Mitomycin Activation Cascade: A Practical Synthesis of an Aziridinomitosene. J. Am. Chem. Soc. 1988, 108, 4648-4650.
41. (d) Kohn, H.; Zein, N.; Lin, X. Q.; Ding, J.-Q.; Kadish, K. M. Mechanistic Studies on the Mode of Reaction of Mitomycin C under Catalytic and Electrochemical Reductive Conditions. J. Am. Chem. Soc. 1987, 109, 1833-1840.
42. (e) Bean, M.; Kohn, H. Studies on the Reaction of Mitomycin C with Potassium Ethyl Monothiocarbonate under Reductive Conditions. J. Org. Chem. 1983, 48, 5033-5041.
43. (f) Siegel, D.; Gibson, N. W.; Preusch, P. C.; Ross, D. Metabolism of Mitomycin C by DT-Diaphorase: Role in Mitomycin C-induced DNA Damage and Cytotoxicity in Human Colon Carcinoma Cells. Cancer Res. 1990, 50, 7843-7849.